SCHEMBL2360580

SCHEMBL2360580

CCOC(=O)c1cc(C)n(Cc2cccc(C(=O)O)c2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.47
POLB P06746 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 3/20 0.46
HPGD P15428 2/20 0.46
GAA P10253 1/20 0.46
KDM4E B2RXH2 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
LMNA P02545 3/20 0.46
MEN1 O00255 1/20 0.46
MAPK1 P28482 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
PTGER1 P34995 2/20 0.44
ALDH1A1 P00352 1/20 0.44
FAAH O00519 1/20 0.44
TP53 P04637 2/20 0.44
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44
PKM P14618 1/20 0.44
NFKB1 P19838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1233306 0.87 SMN1; SMN2 (0.60) SMN1; SMN2POLBKMT2AGAALMNA
SCHEMBL2364609 0.86 SLC7A5 (0.46) SMN1; SMN2POLBKMT2AHPGDGAA
Bicarbonate SCHEMBL2360581 0.86 SMN1; SMN2 (0.58) SMN1; SMN2POLBKMT2AGAALMNA
SCHEMBL29699784 0.84 CYP19A1 (0.57) SMN1; SMN2POLBKMT2AHPGDLMNA
SCHEMBL2360281 0.83 IDO1 (0.51) SMN1; SMN2POLBKMT2AGAALMNA
SCHEMBL27715515 0.81 HTT (0.56) SMN1; SMN2POLBHTTKMT2AGAA
SCHEMBL15956989 0.80 MEN1 (0.57) SMN1; SMN2POLBKMT2AHPGDGAA
SCHEMBL15964667 0.78 ALDH1A1 (0.48) SMN1; SMN2POLBKMT2AHPGDGAA
SCHEMBL20502190 0.78 KMT2A (0.60) POLBKMT2AGAAKDM4ELMNA
SCHEMBL29699814 0.78 MEN1 (0.61) SMN1; SMN2POLBKMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356113-B1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER IP GMBH (DE) 2015-01-07 EP disclosed
EP-2356113-B1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER IP GMBH (DE) 2015-01-07 EP disclosed
US-20130196964-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-08-01 US disclosed
US-20130196964-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-08-01 US disclosed
EP-2356113-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2011-08-17 EP disclosed
WO-2010054763-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 WO disclosed
WO-2010054763-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196964-A1 HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS HIF1AN, HIF1A, VHL SMN1; SMN2 4248/4885POLB 1500/4885HTT 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.